Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

of annual physicals for children before the school year.

Seasonal Influenza

The majority of individuals with influenza recover in less than two weeks; however, some may develop life-threatening complications such as pneumonia. In addition, influenza exacerbates the symptoms of chronic health conditions such as diabetes, asthma and congestive heart failure. The most severe disease occurs in infants and young children and adults older than 65 years of age. The CDC reports that 15 to 60 million people in the U.S. contract influenza each year leading to over 200,000 hospitalizations and 36,000 deaths. The Advisory Committee on Immunization Practices ("ACIP"), which has been expanding recommendations for seasonal influenza vaccination for the last several years, currently recommends seasonal influenza vaccination for children 6 months through 18 years of age, pregnant women, adults over 50 years of age, and individuals of any age with chronic health conditions or who are at high risk of influenza disease. Based on the expanding recommendation of vaccination to new age groups, the growing worldwide population to be vaccinated, and the need of an improved influenza vaccine for the elderly, global market projections of seasonal influenza are estimated to increase from $2.8 billion in 2007 to $6.5 billion by 2013.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development result
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Dallas, Texas (PRWEB) October 30, 2014 ... China Naltrexone HCL Industry” is a professional and ... The report provides basic Naltrexone HCL information, including ... as well as industry overview. This research covers ... as well as global industry analysis covering macroeconomic ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories ... of the Board, to the National Stem Cell Ethics ... made by the Ministry of Health on behalf of the ... , More than a year after Bahamian Parliament passed the ... Perry Christie said the government has completed the accompanying regulations ...
(Date:10/30/2014)... the key challenges in the development of quantum technologies ... In a paper published today (28 October) in ... how to make a new type of flexibly designed ... as high-precision sensors and specialised superfast computers, often depend ... methods for trapping these tiny particles are hugely problematic ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... Expedites Reporting Process, WALL, N.J., Oct. 24 ... leader in wireless public safety,solutions and finger based ... from the Littleton, Colorado Police Department,to implement the ... is a module of BIO-key,s Mobile Office(TM) solution. ...
... SAN FRANCISCO, Oct. 24 Cell Therapeutics,Inc. ... data presented at,the 19th annual AACR-NCI-EORTC Symposium ... kill tumors refractory to currently,marketed platinum agents ... human clinical trials in late 2008. ...
... (Nasdaq: KERX ) will hold a conference call ... discuss the Third Quarter 2007 financial results.,Michael S. Weiss, ... the call. Keryx will announce its financial results for ... to the call. In order to participate in ...
Cached Biology Technology:BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2
(Date:10/30/2014)... German . ... to behave socially? This is one of the central ... studies assumed that it is almost impossible to control ... Planck Institute for Evolutionary Biology have now demonstrated that ... cooperative behaviour of others. However, the possibilities available to ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... Tenn. Consider the case of the three-spine stickleback. ... fresh water might appear to be the same, yet ... collection of very specialized individuals. Understanding the ... the goal of a group of scientists meeting at ...
... Stephania Cormier, PhD, Associate Professor of Pharmacology ... shown for the first time that early exposure ... ultrafine particulate matter) affects long-term lung function. She ... 11th International Congress on Combustion By-Products and Their ...
... research that allows farmers to harvest rice earlier, giving them ... needed food and ease hunger during monga -- the hunger ... northwest Bangladesh from September to November after the previous season,s ... rice in December. According to the Bangladesh Bureau ...
Cached Biology News:The value of variation: Ecologists consider the causes and consequences 2LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease 2Early rice harvests ease annual famine in Bangladesh 2
... to detect the appearance of AcNPV gp64 ... as early as 8-24 hours post-infection. This ... Kit, which allows determination of baculovirus titers ... FastPlax Antibody can also be used to ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: